Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
NCT07184788Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of glofitamab and polatuzumab vedotin in aggressive B-cell lymphoma. Primary endpoint: Overall Response Rate at 1 year. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
glofitamabpolatuzumab vedotin
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT07184788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184788.